Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated or Viral Neoantigens in a Patient With Metastatic Cancer Plus the Administration of Pembrolizumab
Condition: Metastatic HPV-16 Positive Squamous Cell Anal Cancer Interventions: Drug: Cyclophosphamide; Drug: Fludarabine; Drug: Aldesleukin; Drug: Pembrolizumab (KEYTRUDA(R)); Biological: Individual Patient TCR-Transduced PBL Sponsor: National Cancer Institute (NCI) Enrolling by invitation (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 3, 2020 Category: Research Source Type: clinical trials
A Study to Test BI 754091 Alone or in Combination With BI 836880 in People Who Have Advanced Anal Cancer
Condition: Anal Canal Squamous Cell Carcinoma Interventions: Drug: BI 754091; Drug: BI 836880 Sponsor: Boehringer Ingelheim Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 5, 2020 Category: Research Source Type: clinical trials
Testing the Addition of Nivolumab to Chemotherapy for Patients With Metastatic Anal Cancer
Conditions: Anal Basaloid Carcinoma; Anal Canal Cloacogenic Carcinoma; Metastatic Anal Squamous Cell Carcinoma; Recurrent Anal Squamous Cell Carcinoma; Stage III Anal Cancer AJCC v8; Stage IIIA Anal Cancer AJCC v8; Stage IIIB Anal Cancer AJCC v8; Stage IIIC Anal Cancer AJCC v8; Stage IV Anal Cancer AJCC v8 Interventions: Drug: Carboplatin; Biological: Nivolumab; Drug: Paclitaxel Sponsor: National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 24, 2020 Category: Research Source Type: clinical trials
Testing the Addition of Nivolumab to Chemotherapy for Patients With Metastatic Anal Cancer
Conditions: Anal Basaloid Carcinoma; Anal Canal Cloacogenic Carcinoma; Metastatic Anal Squamous Cell Carcinoma; Recurrent Anal Squamous Cell Carcinoma; Stage III Anal Cancer AJCC v8; Stage IIIA Anal Cancer AJCC v8; Stage IIIB Anal Cancer AJCC v8; Stage IIIC Anal Cancer AJCC v8; Stage IV Anal Cancer AJCC v8; Unresectable Anal Squamous Cell Carcinoma Interventions: Drug: Carboplatin; Biological: Nivolumab; Drug: Paclitaxel Sponsor: National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 24, 2020 Category: Research Source Type: clinical trials
